Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kodiak Sciences Inc (KOD)
Kodiak Sciences Inc (KOD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355,423
  • Shares Outstanding, K 52,345
  • Annual Sales, $ 0 K
  • Annual Income, $ -333,820 K
  • 60-Month Beta 1.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79
Trade KOD with:

Options Overview Details

View History
  • Implied Volatility 107.34% ( +12.49%)
  • Historical Volatility 88.84%
  • IV Percentile 89%
  • IV Rank 60.79%
  • IV High 151.46% on 09/16/22
  • IV Low 38.92% on 12/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 209
  • Volume Avg (30-Day) 461
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 15,556
  • Open Int (30-Day) 12,104

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -1.38
  • Number of Estimates 5
  • High Estimate -1.24
  • Low Estimate -1.53
  • Prior Year -1.74
  • Growth Rate Est. (year over year) +20.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.25 +51.29%
on 05/04/23
7.26 -11.43%
on 05/22/23
+1.47 (+29.64%)
since 04/24/23
3-Month
4.25 +51.29%
on 05/04/23
7.26 -11.43%
on 05/22/23
-0.32 (-4.74%)
since 02/24/23
52-Week
4.25 +51.29%
on 05/04/23
12.80 -49.77%
on 08/11/22
-0.09 (-1.38%)
since 05/24/22

Most Recent Stories

More News
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 6.43 (-5.30%)
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

KOD : 6.43 (-5.30%)
GERN : 3.14 (+2.28%)
Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 6.43 (-5.30%)
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

CRSP : 65.88 (-1.96%)
KALA : 16.63 (-0.54%)
KOD : 6.43 (-5.30%)
IMUX : 1.7400 (-9.37%)
Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

CRSP : 65.88 (-1.96%)
KALA : 16.63 (-0.54%)
KOD : 6.43 (-5.30%)
PALI : 1.4500 (-7.64%)
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

CRSP : 65.88 (-1.96%)
IFRX : 4.21 (-3.00%)
KALA : 16.63 (-0.54%)
KOD : 6.43 (-5.30%)
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

CRSP : 65.88 (-1.96%)
KALA : 16.63 (-0.54%)
KOD : 6.43 (-5.30%)
JSPR : 1.6200 (-5.81%)
Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why

Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.

REGN : 737.40 (-1.49%)
NVS : 100.03 (-0.22%)
RHHBY : 39.8500 (+0.50%)
KOD : 6.43 (-5.30%)
Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 6.43 (-5.30%)
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 6.43 (-5.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent...

See More

Key Turning Points

3rd Resistance Point 7.15
2nd Resistance Point 6.92
1st Resistance Point 6.68
Last Price 6.43
1st Support Level 6.21
2nd Support Level 5.98
3rd Support Level 5.74

See More

52-Week High 12.80
Fibonacci 61.8% 9.53
Fibonacci 50% 8.52
Fibonacci 38.2% 7.52
Last Price 6.43
52-Week Low 4.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar